A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD

Grants and Contracts Details

Description

HUMAN CLINICAL TRIAL - CONFIDENTIAL COG Protocol AAML1031 entitled, “A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD”. SUBCONTRACTE shall carry out the clinical trial research study set forth in the research protocol COG Protocol AAML1031 entitled, “A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD”
StatusActive
Effective start/end date3/31/175/2/25

Funding

  • Public Health Institute: $363.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.